Read More

Genmab, BioNTech Announced Data At ASCO, Showing Investigational Acasunlimab In Combination With Pembrolizumab Resulted In 12-month Overall Survival Rate of 69% In Patients With Previously Treated Metastatic Non-small Cell Lung Cancer

Genmab A/S (NASDAQ:GMAB) and BioNTech SE (NASDAQ:BNTX) todayannounced initial data from the Phase 2 GCT1046-04 trial (NCT05117242) evaluating acasunlimab (DuoBody-PD-L1x4-1BB), an investigational bispecific antibody also


Read More

Gilead And Arcus Announced Etrumadenant Plus Zimberelimab, FOLFOX, And Bevacizumab Reduce Death Risk By 63% And Disease Progression by 73% vs Regorafenib In Phase 1b/2 Trial For Third-Line Metastatic Colorectal Cancer

Gilead Sciences, Inc. (NASDAQ:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced new data from Cohort B of ARC-9, a Phase 1b/2 study evaluating the safety and efficacy of etrumadenant, a dual A2a/b adenosine


Read More

ALX Oncology Reported Phase 1 ASPEN-07 Data In in Patients with Advanced Bladder Cancer AT ASCO 2024; Initial Activity Showed Tumor Reduction In The Majority Of Evaluable Patients

ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (NASDAQ: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today presented dataALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (NASDAQ:


Read More

Frank McCourt Organizes Bid to Acquire TikTok in U.S.

Frank McCourt, Founder of Project Liberty and Executive Chairman of McCourt Global, today announced that Project Liberty is organizing a bid to acquire the popular social media platform TikTok in the U.S., with the goal of placing people and data empowerment at the center of the platform's design and purpose.